Allogeneic Human Cell Therapy

Allogeneic Wharton’s Jelly Application (Umbilical Cord–Derived Biologic) — Experimental Use. This is an elective, experimental application of an allogeneic biologic derived from Wharton’s jelly, the gelatinous connective tissue within the human umbilical cord. Allogeneic means the material comes from a screened donor rather than from your own body. The tissue is recovered with maternal consent following full-term, consented Cesarean deliveries and is processed by U.S.-based, AATB-accredited tissue banks. What it is Wharton’s jelly is a matrix rich in structural proteins and signaling molecules, and a source of mesenchymal stromal cells. These cells are considered relatively immune-evasive, which is why reactions to donor material are uncommon—though, as with any human-derived tissue, not impossible. The cellular content and characteristics of the final product depend heavily on how it is processed and preserved, which varies by manufacturer. Donor screening Every donor is determined eligible for transplantation by a licensed physician retained by the tissue bank, based on medical history, risk-behavior assessment, records review, and physical examination. Donor specimens are tested in FDA-registered, CLIA-certified laboratories for HIV-1/2, hepatitis B and C (including nucleic acid testing and hepatitis B core/surface antigen testing), HTLV-I/II, and syphilis (RPR). Tissue with evidence of, or risk factors for, communicable disease is rejected. Each lot is tracked by allograft ID for post-treatment traceability.